Revving up the immune engine in cHL

Research output: Contribution to journalReview articlepeer-review

Abstract

In this issue of Blood, Armand et al report on a clinical trial of pembrolizumab, an immunoglobulin G4 anti-programmed cell death-1 (anti-PD-1) antibody, administered to patients as consolidation or maintenance therapy after autologous stem cell transplantation (ASCT) for relapsed/refractory (RR) classical Hodgkin lymphoma (cHL).

Original languageEnglish (US)
Pages (from-to)1-2
Number of pages2
JournalBlood
Volume134
Issue number1
DOIs
StatePublished - Jul 4 2019

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'Revving up the immune engine in cHL'. Together they form a unique fingerprint.

Cite this